SYDNEY, Australia, June 30 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis today announced that a U.S. pharmaceutical company has placed an order to purchase Aridol(TM) test kits for a series of asthma trials evaluating its new asthma therapeutic. The phase II trials will be conducted in North America and are expected to commence later this year.
Dr Alan Robertson, Pharmaxis CEO said, "There are many products in development for asthma and a very significant need exists for tests that can demonstrate their therapeutic benefits. Aridol testing fills this need by providing information about the patient's inflammatory status and response to treatment. The standardized and easy to use Aridol testing protocol, backed up by regulatory approval makes Aridol a unique diagnostic tool which we hope will receive widespread acceptance and use in clinical trials".
Aridol is the only asthma test registered in Australia. Pharmaxis has submitted an application for approval in Europe and is in the final stages of a phase III study necessary for filing a marketing application in the U.S. Aridol has been the subject of over 30 peer reviewed publications. Since Pharmaxis expanded its GMP facility and made available a new clinical trial kit, the number of studies has risen to more than 60 worldwide, most initiated by key opinion leaders in respiratory medicine. Aridol can be supplied to companies wishing to conduct clinical trials by referencing the IND granted by the U.S. FDA in 2005.
To find out more about Pharmaxis, go to http://www.pharmaxis.com.au . To find out more about Aridol, go to http://www.aridol.info . Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this press release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.
CONTACT: Alan Robertson - Chief Executive Officer Tel: +61-2-9454-7200 Fax: +61-2-9451-3622 Released through: United States: Brandon Lewis Trout Group Tel: +1-212-477-9007 Email: blewis@troutgroup.com Australia: Ashley Rambukwella Financial & Corporate Relations Pty Ltd. Tel: +61-2-8264-1004 or +61-407-231-282 Email: a.rambukwella@fcr.com.au
Pharmaxis LtdCONTACT: Alan Robertson of Pharmaxis, +61-2-9454-7200, +61-2-9451-3622; orBrandon Lewis of Trout Group for Pharmaxis, +1-212-477-9007, orblewis@troutgroup.com; or Ashley Rambukwella of Financial & CorporateRelations Pty Ltd. for Pharmaxis, +61-2-8264-1004, or +61-407-231-282, ora.rambukwella@fcr.com.au
